For a 10-month-old infant with the chronic hepatitis B infection, what is the recommended management?

For a 10-month-old infant with the chronic hepatitis B infection, what is the recommended management?

• A. Consult a pediatric infectious disease specialist.
• B. Prescribe interferon-alfa.
• C. Provide supportive care.
• D. Consider use of lamivudine.

Answer: (A)

In infants with chronic hepatitis B, the key is specialized evaluation to decide whether treatment is needed and to plan careful monitoring. A 10-month-old who has established chronic HBV requires input from a pediatric infectious disease specialist (or hepatology) to interpret liver tests, HBV DNA levels, serology (like HBeAg status), and the child's overall health. This isn’t a situation where you automatically start an antiviral or rely on supportive care alone; the decision to treat, and which therapy to use, depends on detailed assessment of disease activity and potential drug risks in such a young patient. Referencing a specialist ensures the most appropriate plan, balancing the likelihood of spontaneous resolution versus progression, and arranging ongoing follow-up. Interferon-alfa is not routinely used in infants due to limited data and safety concerns, and lamivudine requires specialist oversight and is considered only in specific scenarios. Providing only supportive care may miss a need for therapy or monitoring that could influence outcomes.

In infants with chronic hepatitis B, the key is specialized evaluation to decide whether treatment is needed and to plan careful monitoring. A 10-month-old who has established chronic HBV requires input from a pediatric infectious disease specialist (or hepatology) to interpret liver tests, HBV DNA levels, serology (like HBeAg status), and the child's overall health. This isn’t a situation where you automatically start an antiviral or rely on supportive care alone; the decision to treat, and which therapy to use, depends on detailed assessment of disease activity and potential drug risks in such a young patient.

Referencing a specialist ensures the most appropriate plan, balancing the likelihood of spontaneous resolution versus progression, and arranging ongoing follow-up. Interferon-alfa is not routinely used in infants due to limited data and safety concerns, and lamivudine requires specialist oversight and is considered only in specific scenarios. Providing only supportive care may miss a need for therapy or monitoring that could influence outcomes.